Brind.
  1. BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.
  2. ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.

BioCryst Pharmaceuticals engaged CareMed for commercial support and is advancing the oral pellet formulation of ORLADEYO.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BioCryst Pharmaceuticals engaged CareMed for commercial support and is advancing the oral pellet formulation of ORLADEYO.

Keep exploring

Part of

ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers. All 1 developments

Within BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.

Coverage

Newest first; wire copies grouped